BioCentury
ARTICLE | Company News

Nuvelo cardiovascular news

March 3, 2003 8:00 AM UTC

NUVO said it is refocusing it development plans on its alfimeprase thrombolytic compound, which is partnered with Amgen Inc. (AMGN, Thousand Oaks, Calif.) and is in Phase I testing for peripheral art...